글로벌 레녹스 가스토 증후군 시장 – 2030년까지의 산업 동향 및 예측

Lennox Gastaut 증후군 시장 분석 및 규모

진행 중인 팬데믹은 제약 및 의료 부문의 역학을 상당히 변화시키고 있습니다. 전 세계적으로 여러 병원, 외래 수술 치료 센터 및 진료소가 첨단 장치와 장비를 도입하고 있습니다. Lennox Gastaut 증후군 시장의 매출 성장은 만성 질환의 유병률 증가, 의료 및 의료 부문의 급속한 발전과 같은 요인에 의해 상당히 주도됩니다.

Data Bridge Market Research는 2023-2030년 예측 기간 동안 Lennox Gastaut 증후군 시장의 성장률을 분석합니다. 예상 CAGR Lennox Gastaut 증후군 시장은 언급된 예측 기간 동안 약 4.60%인 경향이 있습니다. 이 시장은 2022년에 7억 달러로 평가되었으며 2030년까지 10억 312만 달러까지 성장할 것입니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

Lennox Gastaut 증후군 시장 범위 및 세분화

Market Definition

Lennox-Gastaut syndrome (LGS) also known as pediatric epilepsy syndrome or childhood epileptic encephalopathy. It is usually characterized by mental retardation, reduced intellectual powder, multiple tonic-clonic seizures and strange findings on electroencephalography. It is most frequently observed between second and sixth year of the life.

Lennox Gastaut Syndrome Market Dynamics

Drivers

• Prevalence of Lennox-Gastaut Syndrome

According to National Organization for Rare Disease, around 1%-4 % of all cases of infantile epilepsy are caused by Lennox-Gastaut syndrome, which affects 0.1-0.28 people out of every 100,000 people. In addition to this, out of 100,000 children, 2 are thought to be affected by lennox-gastaut syndrome every year, whichcommonly appears between ages  2 to 7, with a peak onset between ages  3 and 5.

• Increasing Awareness About Lennox Gastaut Syndrome

The rising awareness about the diseased condition is spreading much awareness about the diagnosis and treatment of the same. Numerous governmental and non-governmental organizations such as Genetic and Rare Diseases (GARD) Information Center, Epilepsy Society, Genetic Alliance Australia, National Organization of Rare Disorders (NORD) are educating people and providing medical care and support to LGS patients. These organizations are raising awareness about the symptoms, diagnosis, signs, and treatment of LGS

Opportunities

• Rising Demand Of  Non-Surgical Treatment

The non-surgical treatment segment resulted in the highest Lennox-Gastaut syndrome treatment market share due to the recent LGS drug approvals and the higher adoption of ketogenic diet. Thus, this is creating much awareness about the market growth.

• Emergence of New Varied Treatments

Several companies are primarily focusing on the development of minimally invasive procedures such as MR-guided laser interstitial thermal therapy (MRg-LITT). MRg-LITT has become a safe, effective, and durable alternative to traditional open corpus callosotomy. The accurate efficacy of MRg-LITT is also being tested in advanced surgical ablation of epileptogenic foci and corpus callosotomy.

Restraints/Challenges

• Lack of Awareness

For many decades, epilepsy and seizures related disorders have been enveloped in discrimination, stigma, misinformation, and fear, in several parts of the world. The quality of life of people are used to be compromised due to disease's societal stigma, that still exists in many modern-day countries. The stigma connected with ailment may discourage some people from seeking treatment as they don't want to be identified with it.

• High Cost of Treatment Process

The huge expenditure required for its treatment processes impedes the market growth. Several market players make huge investments in manufacturing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.

This  Lennox Gastaut syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Lennox Gastaut syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Lennox Gastaut Syndrome Market Scope

The Lennox Gastaut syndrome market is segmented on the basis of symptoms, route of administration, end-user distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Symptoms

• Medication
• Surgery
• Intravenous Immunoglobulin Therapy
• Ketogenic Diet Products

Route of Administration

• Oral
• Parenteral

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Lennox Gastaut Syndrome Market Regional Analysis/Insights

The Lennox Gastaut syndrome market is analyzed and market size insights and trends are provided by symptoms, route of administration, end-user distribution channel as referenced above.

The major countries covered in the Lennox Gastaut syndrome market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

북미는 신경학 분야에서 활발한 연구 개발 활동과 강력한 제약 산업의 입지로 인해 시장을 장악하고 있습니다.

아시아 태평양 지역은 인식 제고, 잘 확립된 의료 인프라, 의료비 지출 증가로 인해 향후 몇 년 동안 성장할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 또한 글로벌 브랜드의 존재와 가용성, 그리고 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다. 

경쟁 환경 및 글로벌 Lennox Gastaut 증후군 시장 점유율 분석

Lennox Gastaut 증후군 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 Lennox Gastaut 증후군 시장과 관련된 회사의 초점에만 관련됩니다.

Lennox Gastaut 증후군 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 노바티스 AG(스위스)
• F. 호프만-라 로슈 유한회사(스위스)
• 파이저 주식회사(미국)
• Bayer AG(독일)
• 브리스톨 마이어스 스퀴브 회사(미국)
• Novo Nordisk A/S(덴마크)
• GSK 주식회사(영국)
• 아스트라제네카(영국)
• 카딜라 파마슈티컬스(인도)
• Sun Pharmaceutical Industries Ltd. (인도)
• 암젠 주식회사(미국)
• 애벗(미국)
• Sunovion Pharmaceuticals Inc(미국)
• 에자이 주식회사(일본)
• 존슨앤존슨 프라이빗 리미티드(미국)
• Teva Pharmaceutical Industries Ltd.(이스라엘)
• 사노피(프랑스)
• Bausch Health Companies Inc. (캐나다)
• H. Lundbeck A/S(덴마크)
• Marinus Pharmaceuticals, Inc(미국)

SKU-63160